GC101

GENETIC3 trials

Sponsors

GeneCradle Inc

Conditions

SMA IISpinal Muscular AtrophySpinal Muscular Atrophy Type 3

Phase 1

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

RecruitingNCT05824169

GeneCradle IncSpinal Muscular Atrophy

Start: 2023-02-25End: 2026-12-31Target: 18Updated: 2025-07-03

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients

Active, not recruitingNCT05901987

GeneCradle IncSMA II

Start: 2023-08-01End: 2028-12-31Target: 33Updated: 2025-07-03

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

RecruitingNCT06421831

GeneCradle IncSpinal Muscular Atrophy Type 3

Start: 2024-05-10End: 2028-12-31Target: 21Updated: 2025-07-03